AZD4625

MedChem Express

AZD4625

10

Research Use Only

99.52

C24H21ClF2N4O3

486.90

AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer[1][2].

C=CC(N1C[C@H]2N(C3=C4C(OCC2)=C(Cl)[C@@]([C@@]5=C(F)C=CC=C5O)=C(F)C4=NC=N3)C[C@H]1C)=O

-20°C

12131703